Brokerages Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $7.80

Key Points

• TScan Therapeutics, Inc. (NASDAQ:TCRX) has received a consensus rating of "Buy" from five research firms, indicating positive sentiment among analysts.
• The firm's 1-year target price has been set at an average of $7.80, with shares currently trading around $1.79.
• Institutional investors own approximately 82.83% of TScan's stock, highlighting significant backing from financial institutions.

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average rating of "Buy" from the five research firms that are presently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $7.80.

Several research firms recently issued reports on TCRX. Wedbush reissued an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a research note on Tuesday, August 12th. Wall Street Zen raised shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th.

TScan Therapeutics Stock Performance

Shares of TCRX traded down $0.01 during trading on Monday, reaching $1.78. 166,809 shares of the company traded hands, compared to its average volume of 219,576. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $6.23. The stock has a 50-day simple moving average of $1.79 and a 200-day simple moving average of $1.60. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.06 and a quick ratio of 7.06.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28). TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. The firm had revenue of $3.08 million during the quarter, compared to the consensus estimate of $1.31 million. Equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TCRX. Wellington Management Group LLP raised its holdings in shares of TScan Therapeutics by 5.2% in the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company's stock valued at $404,000 after purchasing an additional 6,550 shares in the last quarter. Woodline Partners LP increased its holdings in TScan Therapeutics by 6.7% in the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company's stock valued at $352,000 after buying an additional 7,282 shares during the last quarter. Aberdeen Group plc raised its stake in TScan Therapeutics by 0.9% in the first quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock valued at $1,230,000 after buying an additional 7,744 shares in the last quarter. Boothbay Fund Management LLC lifted its holdings in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company's stock worth $35,000 after buying an additional 8,121 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company's stock worth $235,000 after acquiring an additional 9,676 shares in the last quarter. Hedge funds and other institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.